This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk04: Hello, and welcome to ResMed's third quarter fiscal year 2023 earnings call and webcast. If anyone should require operator assistance, please press star zero on your telephone keypad. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Amy Wakeham, Chief Communications and Investor Relations Officer. Please go ahead, Amy.
spk10: Great. Thank you, Kevin. Hello, everyone, and welcome to ResMed's third quarter fiscal year 2023 earnings conference call. This call is being webcast live, and the replay will be available on the investor relations section of our corporate website later today, along with a copy of the earnings press release and the presentation, both of which are available now. On the call today are Chief Executive Officer Mick Farrell and Chief Financial Officer Brett Sandercock. Following our prepared remarks, Mick and Brett will be joined by Rob Douglas, President and Chief Operating Officer, and David Pendarvis, Chief Administrative Officer and Global General Counsel, for our Q&A session. During today's call, we will discuss several non-GAAP measures. For a reconciliation of the non-GAAP measures, please see the supporting schedules in today's earnings release. Our discussion today will include forward-looking statements, including but not limited to expectations about our future financial and operating performance. We believe these statements are based on reasonable assumptions. However, our actual results could differ. Please review our SEC filings for a complete discussion of the risk factors that could cause our actual results to differ materially from any forward-looking statements made today. I'd like to now turn the call over to Mick.
spk06: Thanks, Amy, and thank you to our stockholders for joining us today as we review the results for the March quarter. Our third quarter fiscal year 2023 financial results reflect very strong performance across our entire business. Through the hard work of our ResMed team worldwide, we've been able to steadily improve supply and manufacturing output to deliver for customers and most especially for patients with now full market availability of our lifesaving products and therapy solutions. During the quarter, we were able to offer unconstrained access to cloud-connected AirSense 10 flow generator devices in North America, as well as improved access to those cloud-connected devices across our global markets. We continue to work through some supply chain constraints with our latest and greatest AirSense 11 platform, and we expect to steadily improve the global availability of AirSense 11 over the next several quarters. We are thrilled to have the Essence 10 platform off allocation and fully available to customers in the US and other major markets in swift succession. I would like to send a huge personal thank you to our Six Sigma Black Belt supply chain and our manufacturing teams. Partnering with our global supplier alliance, we have been able to significantly increase production to the point that we are now able to deliver cloud connected devices to meet the needs of all of our customers in the US, and we are working hard to make that the case in all 140 countries that we sell into worldwide as we move forward. Last quarter, we made a commitment to meet the global demand for connected CPAP and APAP devices with a combination of AirSense 10 and AirSense 11 by the end of calendar year 2023. As I just noted, we have already achieved that goal in our largest market. And we will be well ahead of that goal across all of our global markets. Supply chain challenges aren't completely behind us, but we have passed the nadir in supply and we see steady increases in supply ahead. Our amazing R&D teams and global supplier alliance teams have designed and validated new components. They have added new suppliers and they have worked hand in hand with existing suppliers to secure the flow of parts that we need. We're also focused on scaling our manufacturing capabilities with the world's biggest and highest output manufacturing plant on the planet in the field of respiratory medicine. That high-tech facility is now fully up and running in Tuas, Singapore. We are working country by country to secure the necessary regulatory approvals as we ramp production and delivery of the Essence 11 platform across global markets. Given this global ramp plan, we expect to remain on our location for the AirSense 11 platform for the next few quarters, with AirSense 10 covering all the difference in demand. With this combination of Air 10 and Air 11, we have the two best sleep apnea therapy platforms in the market, and we are now able to service all of our customers' needs. Our incredible growth rate of 43% in global device revenue this quarter speaks to that market leadership position of these two platforms, customers are voting with their wallets. Our mask and accessory business also continued its strong growth trajectory with 15% global growth in constant currency this quarter across our masks businesses. Mask growth is supported by both new patient growth as well as enhanced resupply programs to existing patients catalyzed by ongoing core patient demand. We have now reached the point that new patient flow is well above the levels we saw pre-COVID. In fact, March, as we just finished, March 2023 was our highest quarter ever for new patient setups in our cloud-based patient management system called AirView. Our digital health ecosystem enables and drives long-term adherence. pushing towards 90% adherence for our highest performing customers. Even as we now pass three years since the start of COVID, there continues to be sustained heightened awareness by patients of the importance of respiratory hygiene and respiratory health. This has been a major step change that has held for now 12 quarters. We consider that a permanent change at this point. In the US market, customers resupply programs including Bright tree resupply have augmented growth. In our consumer-driven markets, outreach programs and subscription programs have also driven mask replenishment rates. Patients want fresh equipment because there is less leak and more comfort for them, the person who was suffocating before this treatment. Physicians want fresh equipment because they have seen peer-reviewed, published evidence that patient resupply is directly correlated to increased patient therapy adherence. Our teams continue to work incredibly hard to achieve these double digit growth results amid a challenging industry environment. All 10,000 of us ResMedians are laser focused on continuing to deliver both the devices and masks for our customers globally every week, every month, and every quarter. Let's now briefly review updates on the top three strategic priorities for our company. Number one, to grow, expand the reach of, and differentiate our core sleep apnea and respiratory care businesses. Number two, to design, develop, and deliver market leading devices as well as market leading digital health solutions that can be scaled globally. And number three, to create, innovate, and grow the world's best software solutions for care delivered outside the hospital. The launch of and market reaction to our AirSense 11 device platform continues to go very well. Patient feedback remains very positive and we continue to see strong adoption of our MyAir patient app. In fact, Air 11 adoption rates of MyAir are more than double the adoption rate of MyAir with the AirSense 10 platform. It turns out that patients love getting their own data every day on their MyAir app with a daily score, daily coaching, therapy engagement through advanced analytics, and patient-focused algorithms. Patient utilization of a digital health platform like MyAir is directly linked to adherence. which is then directly linked to better patient outcomes as seen by the physician, which ultimately drives better outcomes for the payer and the provider. Given these trends, increasing production and global availability of the AirSense 11 platform clearly remains a top priority and an obligation, and we will continue to drive market penetration, leading the market, expanding the market as we scale production and achieve regulatory approvals country by country. Meanwhile, we continue to improve the software and digital health technology that drives a significant component of the value proposition for our connected devices. Over the next several quarters, we will introduce several artificial intelligence-driven coaching features into the AirView system, as well as on the patient-facing MyAir app. These AI algorithms will provide personalized suggestions to improve the patient experience and ultimately to increase patient therapy adherence. Many of these AI-driven solutions will be available on both the AirSense 10 and the AirSense 11 ecosystems. ResMed's AirSense 11 device is the best positive airway pressure device on the planet, followed very closely by the second best device, which is the AirSense 10 platform. And together, they share the same digital health technology ecosystems. We will continue to invest in the ecosystem, supporting these platforms as we innovate solutions for the benefit of physicians, providers, and especially patients. The bottom line is that our digital health technology investments have a multiplier effect across both Air 10 and Air 11 ecosystems, catalyzed and powered by AirView and MyAir. Pivoting to our respiratory care business, We continue to drive growth and adoption of our bi-level and other non-invasive ventilator solutions around the world, as well as investing in our newer-to-market technologies for patients including neuromuscular disease, COPD, and asthma, and beyond. During the quarter, we announced a pilot collaboration between our digital therapeutics team under the Propeller Health brand and the University of California Davis Health System. This partnership allows eligible UC Davis Health patients to have access to Propeller's digital therapeutics platform, including sensors for inhaled medications, a mobile app, a web portal, as well as ongoing patient support. Data from the Propeller sensors will be transmitted to the UC Davis Health's electronic health record system through an API to support patient enrollment and remote patient monitoring. It's still early days for this technology. However, combined with our investments in clinical research for home-based high-flow therapy for the treatment of COPD in the home, we see these technology innovations as important clinical additions for treating respiratory disease and an integral part of our 2025 growth strategy as we now pivot to look beyond to ResMed 2030. Turning to our software as a service offerings for care delivered outside the hospital, our SAS business grew strongly at 35% year over year in the quarter, including the contribution from our recently acquired Medifox Dahn team in Germany. On an organic basis, SAS growth in the quarter achieved high single-digit growth of 9% across our SAS portfolio. We're excited about the strong, sustainable growth of our core SAS business, And we are very pleased to see Medifox Darn contributing to our growth in its first full quarter as part of the global ResMed group. We continue to grow with customers that deliver care outside the hospital as they increase utilization of our software and data solutions to improve and optimize business efficiencies and patient care. Here at ResMed, we believe the future of healthcare is in lower cost, lower acuity settings. We are investing in technology that our customers need to operate and scale as patient volumes grow in these facilities and out of hospital facilities. As the post-COVID patient census continues to improve in our facilities verticals, we are seeing pent-up demand for technology investments that continue to come to market across skilled nursing facilities, nursing homes and beyond. Our home medical equipment SaaS business under the Bright Tree brand continues to grow at a very rapid pace and deliver sustained profitable growth. We are seeing the ongoing impacts of staffing shortages across all of the outside hospital healthcare verticals that we serve. This pressure on our customers provides opportunities to drive conversations about the benefits of our software solutions to streamline and drive efficiencies across their businesses so that they can free up staff to focus on their core purpose of serving patients and improving patient outcomes. Our SAS business remains an important part of ResMed's growth strategy, and it complements the market-leading software and device solutions that we have in our core sleep apnea and respiratory care businesses. Our Bright Tree resupply program continues to demonstrate the synergies we can generate between our SAS business and our core SRC business. Bright Tree Resupply automates the entire process from contacting the patient, interacting with the payer on coverage, communicating directly with the patient, collecting co-pays, and managing the logistics and distribution process of product. The ultimate goal is to keep a CPAP, APAP, or bi-level therapy user replenished with the supplies that they need to enable a better and longer lasting therapy experience. This results in better outcomes for the patient, the physician, the provider, and the payer. We are well positioned as the leading global strategic provider of SAS solutions for outside hospital care globally, and we have created differentiated value for our customers and long-term sustainable growth for our stakeholders. We are transforming out-of-hospital healthcare at scale, leading the market in digital health technology across our business. We now have over 14.5 billion nights of medical data in the cloud. And we have over 20.5, 100% cloud connectable medical devices on bedside tables in 140 countries worldwide. We are liberating data to the cloud every day and unlocking value for patients, for providers, for physicians, for payers, and entire healthcare systems. We are leading the industry and we won't stop innovating. We're investing 7% of our revenue in R&D. It's worth noting that the annualized revenue pool is now well north of $4 billion. There is so much opportunity ahead of us. It's inspiring and it's exciting. ResMed's mission remains crystal clear. We have a goal to improve 250 million lives through better healthcare in 2025. This patient-centric mission drives and motivates ResMedians every day, We made excellent progress towards that inspiring goal with our growth over the last 90 days. And during the last 12 months, we have improved over 156 million lives with the delivery of a device platform to a patient or a full mask system to a patient or a digital health software solution that directly impacts a patient, helping each person to sleep better, to breathe better, and to live a high-quality life with healthcare delivered right where they live. Let me close my remarks with my sincere gratitude to the more than 10,000 ResMedians working across 140 countries for their perseverance, their hard work, and their dedication today and every day. Thank you. With that, I'll hand the call over to Brett in Sydney for his remarks and then get in the queue because we will open up for Q&A from the group. Brett, over to you.
spk15: Great. Thanks, Mick. In my remarks today, I will provide an overview of our results for the third quarter of fiscal year 2023. Unless noted, all comparisons are to the prior year quarter. We had strong financial performance in Q3. Group revenue for the March quarter was $1.12 billion, an increase of 29%. In constant currency terms, revenue increased by 31%. Revenue growth reflected improved availability of sleep devices to support the strong underlying demand for these products, as well as solid growth across our broader product portfolio. Year-on-year movements in foreign currencies, in particular a weaker euro, negatively impacted revenue by approximately 20 million in the March quarter. We recorded incremental revenue of approximately 15 million from COVID-related demand in the March quarter, However, looking forward, we expect negligible revenue from COVID-related demand. Looking at our geographic revenue distribution and excluding revenue from our software as a service business, sales in US, Canada and Latin America increased by 32%. Sales in Europe, Asia and other markets increased by 28% in constant currency terms. Globally, in constant currency terms, device sales increased by 43%, while masks and other sales increased by 15%. Breaking it down by regional areas, device sales in US, Canada, and Latin America increased by 48%, as we benefited from strong demand and improving availability of our connected devices. Masks and other sales increased by 14%, reflecting solid resupply and growth in new patient setups. In Europe, Asia and other markets, device sales increased by 36% in constant currency terms, again reflecting strong demand and improving availability of connected devices. Masks and other sales increased by 15% in constant currency terms, reflecting increased patient setups. Software as a service revenue increased by 35% in the March quarter, reflecting the contribution from our Medifox Darm acquisition and continued strong performance from our HME vertical. Excluding our Medifox Darn acquisition, SAS revenue grew by 9% in the March quarter. Medifox Darn contributed revenue of $26.6 million for the March quarter, consistent with our expectations at the time of the acquisition. During the rest of my commentary today, I will be referring to non-GAAP numbers. We have provided a full reconciliation of the non-GAAP to GAAP numbers in our third quarter earnings press release. Gross margin declined by 200 basis points to 56.1% in the March quarter. The decrease primarily reflects product mix shifts due to significant increase in sleep device sales as well as component cost increases and unfavorable foreign currency movements, partially offset by increases in average selling prices. Moving on to operating expenses, SG&A expenses for the third quarter increased by 25%, or in constant currency terms, increased by 28%. The increase was predominantly attributable to increases in employee-related costs and travel expenses, as well as the incremental SG&A expense associated with our Medifox Darn acquisition. SG&A expenses as a percentage of revenue improved to 20.5% compared to the 21.1% we recorded in the prior year period. Looking forward and subject to currency movements, we expect SG&A expense as a percentage of revenue to be in the range of 20% to 22% for the balance of fiscal year 23. R&D expenses for the quarter increased by 14% or in constant currency terms increased by 16%. R&D expenses as a percentage of revenue was 6.8% compared to 7.7% in the prior year quarter. Looking forward and subject to currency movements, we expect R&D expenses as a percentage of revenue to be in the range of 7% to 8% for the balance of fiscal year 23. Operating profits for the quarter increased by 27%, underpinned by strong revenue growth, partially offset by a lower gross margin. Following the acquisition of Medifox Darn, our net interest expense for the quarter was $15 million and we expect interest expense to be a similar amount for the balance of fiscal year 23. Our effective tax rate for the March quarter was 20% compared to the prior year quarter effective tax rate of 21.1%. Looking forward, we estimate our effective tax rate for fiscal year 23 will be in the range of 19% to 21%. Our net income for the March quarter increased by 28% and non-GAAP diluted earnings per share increased by 27%. Cash flow from operations for the quarter was $283 million, reflecting solid underlying earnings, partially offset by a modest increase in working capital. Capital expenditure for the quarter was $29 million. Depreciation and amortization for the quarter totaled $44 million. We ended the third quarter with a cash balance of $228 million. As of March 31, we had $1.6 billion in gross debt and $1.4 billion in net debt, reflecting the funding of our previously announced Medifox Darn acquisition. During the quarter, we reduced our revolver debt by $215 million. As a result, at the end of the quarter, we have approximately $605 million available for drawdown under our revolver facility and we continue to maintain a solid liquidity position. Our Board of Directors today declared a quarterly dividend of $0.44 per share. Going forward, we plan to continue to reinvest in growth through R&D, reduce our overall debt levels, and deploy further capital for tuck-in acquisitions. And with that, I'll hand the call back to Amy.
spk10: Great. Thank you, Brett, and thank you, Mick. Kevin, I'd like to now turn the call over to you to provide instructions and then run the Q&A portion of the call.
spk04: Certainly. We'll now be conducting a question and answer session. We ask you to please ask one question, then return to the queue. If you'd like to be placed into question queue, please press star 1 at this time. A confirmation tone will indicate your line is in the question queue. You may press star 2 if you'd like to move your question from the queue. Once again, that's star 1 to be placed into question queue, and we ask you to please ask one question, then return to the queue. Our first question is coming from Leanne Harrison from Bank of America. Your line is now live.
spk00: Yeah, good morning all. Before I start, I want to say thank you to David Pendarvis. You know, we're certainly sad to see him retire, but we know that we're in safe hands with Amy. In terms of my question, obviously some very good device revenue there. But, you know, I wanted just to talk about the, you mentioned the third quarter, you had a new patient high, higher than what we've seen pre-COVID. Can you provide some comments of how much of that new patient backlog remains and also what sort of progress you're making on the repat backlog? And if you can discuss that, you know, according to the Americas and rest of the world separately, that would be very helpful.
spk06: Well, thanks for the question, Leanne, and the tribute to Dave for his 20-plus years, 22 years of – I think this is his 83rd investor call, 8-3 – So, amazing tribute to Dave, and we are in very safe hands with Amy on the Investor Relations front. To your question, look, yeah, incredible growth, 43% growth in device revenue this quarter to an all-time high. You know, many factors that have gone into that, primarily that we were able to deliver on our promise to get unconstrained on Essence 10, 100% connected devices, and we've got those at market. And so, I think... You know, we were able to take care of all of the demand of customers in the US market, period, end of story. We said we'd be there by the end of this calendar year, but we're there already here right now. And as I said in the prep remarks, we're going to be scaling the assets 11, you know, steadily and strongly as that new platform, the latest and greatest comes to market and we move forward. In terms of backlog of those sort of new patients, I think we're there in the US. But in terms of repapping, I think there's a lot more to do. And we're going to partner across the US with all of our thousands of home medical equipment companies to start to work through that repap program. But I think that's going to happen over time. We just got to the point where we're completely unconstrained on Essence 10 in this quarter. I think it's fantastic. I want to get unconstrained on AirSense 11. That's going to take a few numbers of quarters. And then, of course, you know, that's just one country. We're in 140 countries worldwide. We've got to go get regulatory in all of them and then get those products to market. And so it's going to be an ongoing process over the coming quarters and years to continue there. You know, I'm not going to say that we're going to see this sort of exceptional 43% growth, you know, on an ongoing basis. The market growth is closer to the mid to high single digits in this space. But we're seeing that market growth come back. We're seeing the new patients come back. We are through that pandemic side and we're getting new patient flow. We see it in our home sleep testing data. We're looking at all the stuff coming through ApneaLink Air. We're seeing it in the number of patients being set up in AirView. All time high, but we're looking at that every week, every month and every quarter and it's steadily improving. And it's not just the US. It's in Western Europe, Northern Europe and it's certainly coming through Asia. Very strong growth in China. over the last number of quarters as we've come through the COVID crisis there as well. So that's my summary there, Leanne. Great question.
spk00: Sorry, can I just clarify, when you said that you're there on the backlog, is that both for the United States and rest of the world?
spk06: Yes, so we're through the backlog in the US and we're going to be progressively working our way through the other 139 countries. You know, it's not... It's a complex system where when you get regulatory approval, say for the SN11, you've got to go region by region. You can do European Union, but then you have to go country by country for many of these. approaches for Brazil, for China, for India, and it takes time to get them there to get unconstrained with the two-platform approach that we've been able to take in the US, Canada, and a number of other countries. But look, we'll give you updates over the coming quarters. Leanne, as we get unconstrained country by country, we'll report it to you. And our goal is to be unconstrained everywhere tomorrow. It's just not logistically possible to be able to do that. So we're going slowly and steadily to that. But I'm just happy to be nine months ahead of when we were saying we're going to deliver an unconstrained at least in some of our top markets here, and we'll keep you updated as we go forward.
spk00: Okay, thank you very much, Mick.
spk04: Thanks, Leanne. Thank you. Next question is coming from Dan Hearn from MS Team. Mark, your line is now live.
spk02: Good morning. Thanks for the question. Look, I might let someone else ask the gross margin question, but I'd like to ask about the SG&O and just the fact that it's remained relatively constant as a percent of revenue. during the course of the recall, which is considered a bit counterintuitive when you consider the fact that the products have been in shortage and certainly selling themselves. I just wondered if we could talk about the key elements of that SG&A and the mid- to long-term trajectory there as volumes continue to improve.
spk06: That's a great question, Dan. I'll hand over to Rob Douglas, our present Chief Operating Officer, to cover our SG&A.
spk05: Yeah, Dan, so you know us and you know how we operate. No matter what's going on, we're fiscally disciplined and we're always keeping an eye on the future and where we're going and what's happening as we build in expenses. We absolutely talked about the fact that we weren't doing face-to-face marketing and a lot of travel and those types of things earlier in the pandemic, and as that started to come back, we've had to manage carefully how that's been an extra load on our SG&A, but it's really really a factor of careful management. Everyone's aware of the issue of employee costs and those things which are moving in the time of inflation and we continue to manage that carefully and we're extremely prudent about what we add in on and how we go. So we really don't want to get ahead of ourselves and end up like some of these other companies that have found them way over provisioned in their go to market operations and had to make corrections. So we're in good shape and we've got a solid plan and We should be able to stick very carefully with Brett's forecast on our SG&A.
spk04: Thank you. Our next question today is coming from Matthew Cheviere from Citi. Your line is now live.
spk11: Good morning. Thanks very much for taking my question. Good afternoon to those in California. You obviously had a very strong devices growth in the quarter. I was just wondering whether you still believe that you can sequentially grow every quarter in fiscal year 23 in devices, and then how should we think about FY24 and the potential return of Philips to the market, and whether there's been any update there.
spk06: Yeah, thanks for the question, Matthew. And yeah, last quarter I certainly said that we expect to see sequential growth of devices throughout the calendar year actually here through 2023, and that was our forecast. I got to tell you this, $607.9 million of device sales in the quarter was ahead of where I thought we were at that point. That's a big number to come up. And as Brett said, there's about 15 million of ventilator sales to China in there as they went through another phase of COVID as they reopened during the March quarter. So if you take that out, It's still a big number to shoot for here in Q4. But we have the best commercial teams on the planet in respiratory medicine sales. And Q4, for us, our fiscal year Q4 is a big time. There's presence clubs in some geographies. There's fiscal incentives everywhere for people to finish their fiscal year strong. And so there's a lot of incentives. So yeah, it's a tough number to get there on sequential growth, taking out those ventilators. I think we can do it. I'm confident in my team. I'll back my team. They got a little bit ahead of me here in March, and I love that. I'd love them to be a little bit ahead of me in June, and so I'm confident we can do that. More important than that is that we are now taking care of every patient's needs in our major markets, and our goal is to be there in all 140 countries. So some of it is that revenue growth, and it's amazing, but it's really about patient care, and it's about leaving no patient behind. And it was really disappointing, I think, for us as an industry. Some of these quarters over the last eight quarters, as an industry, we weren't able to take care of every patient that got a prescription. We're now doing that in our major markets. And we plan to absolutely fulfill that, not only where we've already achieved it, but to get ahead of it in all the other countries as we go. So sequential growth is good. We're going to be pushing towards trying that. But more important than that, taking care of every patient in every geography. and working as hard as we can to get to those patients and get them a well-quality mask and get them on a resupply program because that's what leads to long-term adherence, not just that one-time device sale, but getting an adherent patient that 87, 90-plus percent adherence rates on not just a 90-day basis, but an ongoing basis. That's our challenge, Matthew. Great question, thank you.
spk11: Thank you.
spk04: Thank you. Next question is coming from Gretel Janou from Credit Suisse. Your line is now live.
spk12: Thanks, good morning all. I'll ask the gross margin question. Is the mix really the key driver of the weaker gross margin here? Is the high price offsetting component costs? And just as we look forward, if you're going to continue to assume strong device sales growth, should we expect gross margins to continue to be weaker at these levels in the short term? Thanks.
spk06: Yeah, thanks for the question, Gretel. And as you said, and as Brett said in his prep remarks, you know, we had some headwinds on gross margin, which were geography mix, where, you know, it was more in low margin countries, US, Canada, and then product mix. You know, we saw more CPAP and APAP growth than we did bi-level or life support or even other non-invasive ventilators. And so, you know, those headwinds are going to start to subside. But, you know, I am actually, I think, Gretel, that, you know, as I look forward, I see gross margin expansion in double digit basis points ahead for the coming quarters and throughout the fiscal year and the calendar year. I'm bullish on gross margin expansion because I see geography mix and product mix headwinds subsiding. I'm bullish on gross margin as I see ventilator growth opportunities start to come back and I see mass growth. and replenishment growth, new patient growth start to come on masks. And I'm bullish on gross margin as we go forward because I see inventory costs starting to, we're going to start to cut into that and bring them down versus the run up we had with our competitor being out of market. And I also, I'm bullish on gross margin because I see us being able to get better freight costs as we go forward. And as you said, we have been offsetting some of that. gross margin headwinds with ASP holding steady in our core business, increasing ASPs in our SaaS businesses. And we've had some freight surcharges and others with customers. As we start to see our costs come down, we'll take away some of those surcharges and so on, and so we'll balance that out. But net-net, I see us being able to expand our gross margin and grow as we look forward throughout not just the fiscal year here at 23, but the calendar year here in 23.
spk04: Thank you. Next question is coming from Matt Taylor from Jeffries. Your line is now live.
spk18: Hi. Thanks. Sorry I was on mute. I just wanted to ask about how much we should expect the mask trend to start following the device trend as you become more unencumbered. I thought maybe there would be a little bit more mask growth this quarter, not taking away from a good result. But maybe you could talk about that as a derivative.
spk06: Yeah, thanks, Matt, for your question. And you know that as you look at our masks and accessories business, it's sort of 70% to 80% of our masks growth is replenishment. It's existing patients out there who are coming back for a fresh mask, a fresh humidifier, a fresh set of tubing, heated tubing, and so on, and filters. So it's the mask and accessories is 70, 80% replenishment business. And so it's not as directly impacted. So new patient growth is incredible. We're back to better than pre-COVID and we're growing from there. And that's great to see that sort of strong growth of new patients coming in. But it doesn't sort of directly correlate to your point It's less a derivative and more a sort of a compounding effect over time, like compound interest as you build up that installed base those patients are ordering. If they are ordering on a three-month or six-month basis, that becomes a compounding effect on the device growth today, leading to a future investment in growth in masks over the coming fiscal quarters and fiscal years as you build that installed base. So there's not a direct correlation. 43% device growth doesn't immediately correlate to mask growth. But I mean, to your point, 15% global mass growth on a constant currency basis is incredible. Pre-COVID, we would have been very proud of a number like that. Post-pandemic, coming through this growth, I'm incredibly proud of the team and what they're able to do, not just in new patient setups, but in the replenishment programs. And as I said in the prepared remarks, it's not just in the reimbursed markets where we've got formalized systems. In France, the US, Japan, we have formalized systems to go with our customers to patients to ensure if they want it, that the patient gets a mask when they need it. We're also working in our consumer driven markets where we're driving adherence programs, subscription programs that are fast growing in many of our geographies where it's cash pay or direct to consumer interaction. And they're saying, I want a fresh mask. And so it's true to the core demand. It's not just a system driven one. This is a patient driven one. And that's the part about mask growth that I think is most exciting. Final thing I'll say on mask growth, is that I think there were some skeptics, you know, two or three years ago, people like, oh, this step up in respiratory health and hygiene, step up in mask replenishment, that's a short-term trend due to COVID pandemic. We're three years since the start of this COVID pandemic, and that has been 12 quarters of strong mask growth. So I think that strong mask growth is sustainable for the future. We've been able to execute for 12 quarters, and we plan to continue to do that as we go forward.
spk18: Thank you, Matt. Very helpful.
spk04: Thanks, Matt. Thank you. Next question is coming from Michael Pollack from Wolf Research. The line is now live.
spk17: Thank you for taking the question. I'll ask another twist on the mask question. As you've better filled on the device side, especially in the U.S., is there a halo impact in terms of winning share incrementally on the consumable side? Is that a dynamic that's played out recently or could play out over the next year or so? as the device, kind of the urgency to step into the device void abates and you refocus on other priorities.
spk06: Yeah, look, Mike, there's certainly a relationship and, you know, in our commercial teams, they're working with the best platform, the SN11 and the second best platform, the SN10, both of which are better than our competitors. They're also obviously offering the best masks, the best mask portfolio out there. And we have a leading share in that in all 140 countries as well. So there's definitely a synergy effect in that it's the same people talking to the same physicians, the same providers, the same healthcare systems. And so we're there. In addition, there's some sort of clinical technical needs. I mean, we design our products to work better together. Our masks on our devices have far more accurate mask leak detection. They have far more accurate detection of pressure and control of an APAP device or a bi-level device, in particular if it's used on an overlap patient, say, who has obstructive sleep apnea and COPD, you need that IPAP and the EPAP, the pressure control, to be right on. When you use our bi-level with our mask, that's going to be far more accurate, and the physicians know that, and they will script towards that for those patients. And then, you know, for the respiratory therapists doing a setup, they know our products are designed better together. Our teams have shown them the clinical and technical data of how they're designed, And so there is a strong positive synergy effect. So yeah, I do think there's a correlation between them. You can think the sort of simple commercial, I'm in there selling it, but then you look at it from the physician's perspective on clinical and then the therapist's perspective on fit and comfort and leak. So I think all that goes together to show there's some good synergy between our device growth and mass growth over time.
spk04: Thank you. Next question is coming from David Lau from JP Morgan. Your line is now live.
spk03: Thanks very much. Nick, can we go back to gross margins? I mean, if I heard you correctly, you said you expect gross margins to expand into double digits in future. Can I continue down a little bit on what sort of timeframe and are we talking gross margin percentage? Are we talking gross profits? Just trying to understand what you're expecting on that front, please.
spk06: Yeah, David, thanks. I want to hand to Brett to go through more detail, but what I was saying is I expect double digit basis points improvement from where we're at in the quarter. You know, 56.1% I see as the nadir and I want to grow from there. So I see us being able to move that up, I don't know, 10, 20, 30, 50, 100 basis points over the coming quarters and beyond. But Brett, you want to provide a little more detail for David to the headwinds, the tailwinds and all the fun that goes into gross margin?
spk15: Yeah, sure, sure, Mick. Yeah, David, I mean, we wouldn't, we're not going to try and quantify, but when we look at it, we do expect margin expansion over the coming quarters. So if you look at some of the key ones that have hurt us year on year, it's around, it's product mix, obviously, with a massive increase in sleep devices. We had to deal with component cost increases coming through year on year, but that looks to be stabilising there. So there's two big headwinds that we expect will moderate. And then we're working on manufacturing, logistics, freight costs. We're looking at efficiencies. So we're focused back on that now. And again, these should improve over the coming quarters as well. And then on top of that, with the AS11 platform, that does contribute positively to gross margin as well. Now, that one will take time as we roll that out. But if you kind of put in the, I guess you look at it, the headwinds are moderating. We should get a few tailwinds. in manufacturing and logistics. And that kind of gives us the confidence we think we can get that expansion from here on in. Thank you very much.
spk04: Thank you. Next question today is coming from Margaret Cazor from William Blair. Your line is now live.
spk09: Hey, everyone. Thanks for taking the question. I wanted to maybe follow up on some of the patient demand metrics that you guys gave early on the call. I think I heard maybe high single-digit market growth in the U.S. or America. And then should we add REPAPs to that so that that ultimately leads us to a double-digit growth rate? And then how do you think about that, I guess, once Philips does potentially reenter the marketplace? for you guys on a long-term growth. Can you, I guess, continue at that double-digit top-line growth rate? Thanks.
spk06: Yeah, thanks for that question, Margaret. And, you know, there's so much that goes into it. But, yeah, look, we're on the other side of this pandemic, right? Not only just that the pandemic has become an endemic in the way that the world's opening up and we're driving forward, but in our industry, we're now seeing that strong growth of patients that we're really starting to pick up. And, yeah, it's mid to high single digits growth on the patients starting to come through the funnel now and that's really strong. How long that's sustainable and how we can drive it, that's, you know, it's going to be up to us as the market leader. We have the market lead here and we're going to drive awareness programs, we're going to drive demand generation programs, we're going to partner with, I just got an update from a team here in the US market looking at a project to bring patients into the funnel and to drive patients into the funnel and as the market leader, That's really our job to not just accept market growth, but to drive market growth. So this is going to be an active thing that we're going to be looking at as we move forward. And it's very exciting for us to do that. I'm not going to quantify it out. I mean, given where we're at, I know you have your models, everyone on the sell side and buy side has their models. But I would say to that, whatever your models are, think about an active leader engaging in digital awareness, marketing awareness, and driving and curating patients through the channel. And we've learned a lot through the COVID crisis about digital health. about engaging with patients in home testing, in remote setup, and virtual pathways that have really been necessary at the peak of the pandemic and now become a catalyst for future demand generation. So I don't know, Rob or Lucille, if you have any extra thoughts on that?
spk05: Just one other minor point, Mick. That new patient growth is really solid, and there's so many untreated patients. We could see a long-term future in that. but also as we build our long-term adherence programs and start driving long-term adherence, that'll keep the mass growth ahead of that new patient growth, and we see a long-term outlook for that, too.
spk04: Thank you. Next question is coming from Andrew Payne from CLFA. Your line is now live.
spk16: Yeah, hi. Morning and evening, everyone. Just thinking about your ability to retain market share when Philips comes back to the market. It's a bit up in the air still but assuming from the start of FY24. What levers do you think you can pull here to ensure that you do retain market share? Are we looking at things like pricing as a factor or do you think there's other things that will help you retain that share?
spk06: Yeah, thanks for the question, Andrew. And yes, certainly, look, we look at all competition. You know, we've got competitors based in Western Europe and in Asia that we've been competing with very strongly for the last few decades and certainly the last two years. And one competitor who's been out of the market for new patient setups for two years and who knows how much longer, they'll have to come in. That third competitor now will have to come in and start fighting to become the number two share player from a 0% new patient setup share. And We look forward to that. We were beating that particular competitor in 2019 before they had their recall. So I know we'll be able to beat them when they come back in. And so no, our goal is to seed zero share. Our goal is to actually maintain and grow share. As the market leader, that gets more and more difficult to take more and more share. But that's our goal. We have the smallest, quietest, most comfortable and most cloud-connected devices. But more important than that, we've created a digital ecosystem that engages patients with MyAir, doctors with AirView, healthcare systems by APIs that link into Epic or Cerner in the US and healthcare systems around the world and UK and NHS, Northern Europe into government and Western Europe into government-run healthcare systems. And we're engaging with patients in our consumer-driven markets incredibly well. So our goal is to maintain and grow that share, but more important than that, to grow the market. As the market leader, that's sort of our obligation. There are, you know, now with the latest epidemiology, rising up around a billion people with obstructive sleep apnea that needs to be treated worldwide. And if you add in COPD, asthma and insomnia, you're talking 2.5 billion people in our total addressable market. So, you know, you can think about share, but it's really not Coke and Pepsi was out and Pepsi's coming back. This is not a low growth carbonated beverages market. This is a high growth digital health, technology market in medtech and and that's how that's how we're driving it forward but um yeah i look forward to just getting the uncertainty out of this number three player i want them back in let's see and let's uh let's compete and we'll keep our share and grow it and uh and game on look forward to it um and and actually you know one last thing i'll say on that people been talking about when that number three competitor comes back um how will they come back Their CFO last week said, oh, no, we won't be coming in and lowering prices. We'll look to take 2019 prices and add to that with inflation. So, you know, game on. I look forward to it. We've always competed on value. We've always competed on driving that. And it's never been a competition on price for us. We've always been a price premium to the other players. But we save them more money so that the smart customers are using our products because it's more profitable.
spk04: Thank you. Next question is coming from Matthew Michon from KeyBank Capital Markets. Your line is now live.
spk13: Yeah. Hi, Nick. You mentioned at one point that you're getting 90% adherence on some of your best customers. I'm just curious like where that is versus kind of baseline and how you can move that forward with like the rest of your customer base.
spk06: Yeah, Matt, it's a really good question. And so, you know, the peer-reviewed published evidence out there is an 87% adherence number that's been out there for a couple of years. You know, if you look at the average of the market where people maybe aren't using as much of the digital capabilities, the patients aren't using Maya, the doctors aren't using AirView, you know, general industry adherence might be on average 60% to 70%, right, with a competitor device that's not connected or maybe someone who's not fully engaged with the digital ecosystem we have. As they start to get engaged, there's actually peer-reviewed published evidence on this, just adding the doctor using AirView moves up adherence by 10%. So you go from, let's say, an average of 65% to 75% for that customer, just having the doctor use AirView. If the patient uses MyAir, you move up almost another 10%. So for that example, you might go from 75% to 85% adherence, where the doctor's using AirView and the patient's using MyAir. To get to those 90s, you need a really special customer that's really engaged and really investing in tech, that takes our tech and sort of adds algorithms and adds capabilities to it. And we have a number of those sophisticated customers in Europe and the US, and we partner with them, and we do joint development with them, and we love that training. We learn from each other. because together is how we deliver the care. We're a manufacturer and we're a provider of digital health solutions. We work with providers in our biggest countries to get there. And where we don't in smaller consumer-driven markets, we have to pick up the ball and engage directly ourselves. But that 90% is achieved in very rare cases, but that peer-reviewed published evidence shows that it can be done with the tech at 87%. And yeah, to your point, how do we get everyone up to that 87%, that 90%? That is a process of engagement, of training, and that's why I say our share is not only going to stay where it is, but have the chance to grow from that because we are the market leader in this. No one's investing like we are in cloud compute. No one's investing like we are in analytics, in AI, in ML, and engagement with patients and physicians and providers. And we're not doing it alone. We're doing it with the ecosystem, with the patients. We're listening to them, with the physicians and with the providers. Thanks for the question, Matt.
spk04: Thank you. Next question is coming from Saul Hadassin from Baron Joey Capital. Your line is now live.
spk01: Thanks for taking my question. Mick, just a question on Prima Sun. I just noticed this quarter the investment was very low, certainly less than what the guidance had been. So I'm wondering, did something change this quarter and any update on how that project is going? Thanks.
spk06: Yes, it's a great question because it lets us talk to our whole sort of demand generation and engagement approach. I mean, as you know, Prima Sun's a joint venture with Verily in the US market looking to digitally engage, well, digitally identify, engage, and enroll patients in a sort of digital health pathway from sleep concern consumer all the way through to diagnose patient on treatment and management. We have activities through our core, you know, US and North America marketing team. And obviously, in the other 139 countries we operate in, we're looking at other digital ways to engage the billion people who need our help. So look, you know, we're looking at investments, we're at pilot phase of some trials, and we're getting ready to scale some approach with PrimaSan, with US programs and many of the others that were operating in all parts of the world. And so as we start to roll those out, now that we're at the point where we've got full capability to supply, as we said in the prep remarks and throughout the call with AirSense 10 and AirSense 11 as a combination, we can really turn to start to turn the dial up on these demand generation initiatives with undiagnosed sleep apnea patients. And I'm excited to start doing that. So those investments might tick up a little over the coming quarters, but they'll have a huge return in bringing patients into the funnel. So watch this space.
spk04: Thank you. Next question is coming from Suraj Kalia from Oppenheimer and Company. Your line is now live.
spk14: Good afternoon, Mick. Can you hear me all right? Got you loud and clear, Suraj. Perfect. So, Mick, first let me just express my... Thanks to David. David, I wish you have a great retirement. It's been a pleasure dealing with you all these years. So, Mick, a lot of questions have been asked. You know, your comment about AI caught my attention. So, Mick, think about it this way. Suraj comes in. He's gone through the CPAP titration, you know, the sleep lab. Certain parameters have been set by the bi-level variable, whatever. What parameters specifically would your AI ML-based algos tell a patient? And the reason I ask is specifically trying to understand how will you use this to improve compliance? Thank you.
spk06: Well, Suraj, you know, it's a really good question. And we only have five minutes left in the call. I could spend, you know, a whole 50 minutes on it. A lot of those things are actually quite proprietary as we put together these AI and ML models on how we would coach a patient, particularly you talk about a high acuity patient like that on bi-level or ventilation, non-invasive ventilation therapy. But look, yes, certainly, you know, I look at our compliance predictors and our compliance analysis tools that can help empower patients and HME in the US, and just some of the ways in which we're able to use AI and ML to drive prioritization of the most at risk for quitting patients, and those who are so close enough to get there, and those who are definitely there and just need some sort of digital coaching. That sort of triage, if you like, which has previously been done manually, is now going to an automated way. And we've always had some levels of that automation, But to have an algorithm that learns as it goes and to get better and better at it, it just serves the doctor. It serves the respiratory therapist. And both of them are super pleased to see that level of efficiency, reduction of, if you like, the administrative management and focus on the toughest patients, but also making sure that the best patients, you know, get the digital coaching and help that they need. So it's really triaging, compliance, adherence, and beyond. But... Watch this space. We're going to launch a bunch of new products that I'll be able to talk to very specifically what they are and what they do over the coming quarters.
spk04: Thank you. Next question is coming from Craig Longpan from RBC. Your line is now live.
spk08: Thanks for taking my question. I just note the inventory balance has continued to increase. So I was wondering when you might start to see that come down. And also, is there much card to cloud inventory or parts in that number still?
spk06: Yeah, Craig, thanks for the question. It did move up just a little bit in the quarter. I actually have got a very strong target for Andrew Price, president of our operations and the whole manufacturing team, to get that number down because we're through the peak of this and we've got full supply. Let's get that number down. But, Brett, do you want to speak to some of the details of how we're going to turn that inventory number down significantly over the coming quarters and fiscal year?
spk15: Sure. Sure, Mick. Thanks. Yeah, I mean, I characterise it, Craig, that we stabilised that inventory this quarter, and really that drove the really strong operating cash flow that you saw. But I think there's more that we can do, and the aim is to reduce those inventory levels overall. I mean, a number of things we can do, but some of them I point out, we're seeing improvement in lead times, which will help. You know, you've got, I guess, getting from port to port's improved a bit so we can lower inventories. We're continuing to increase sea freight versus air freight, so some of that manifests in inventory, but eventually that kind of stabilises at a ratio. We're tuning safety stock levels now because we've got more predictability on what we need and when we can get supply. And then inventory obviously is future looking, so we're looking to support sales. So we've just got to balance all that. But all that said, I think we're looking for inventory levels, that trajectory to gradually go down over the course of FY24.
spk04: Thank you. Our final question today is coming from Chris Cooper from Goldman Sachs. Your line is now live.
spk07: Thanks, Mick. Thanks for taking the question. Just after your latest thoughts on the diabetes and obesity drugs, please, I guess we had another positive update last night. They do seem to be coming thick and fast at the moment. I guess, could you just share how Rosemead are thinking about these and to what extent their success may have any impact on your business, please?
spk06: Yeah, thanks, Chris. It's a huge market and actually quite exciting. We've always wanted to have interactions. When I first joined the company 23 years ago, we were working with bariatric surgeons and looking at patients that would go through bariatric surgery and maybe from 450 pounds down to 200 pounds. And our challenge in those days when it was mostly a CPAP market was how do we make sure they get on APAP because their needs, their AHI might go from 50 when they were at 450 pounds to 30 when they were 250 pounds. But that 30 is still severe sleep apnea. So we had to have an APAP algorithm that could adjust with them. These days the market is 80% APAP and so you don't need to make sure that a patient on let's say a weight loss drug or or so on that sees a weight loss and their AHI needs go down from, you know, very, very severe sleep apnea to just severe or moderate to severe. We have the algorithms and the capabilities within the devices with our autistic algorithm to adjust automatically. And we'll also have all the digital health data so that the pulmonary doctor can partner up with the primary care or bariatric type doctor that's working on, presumably PCPs working on the obesity drugs And they can monitor the patient to see how much better they're getting, maybe more adherence, more participation in their fitness and exercise for the overall health. So for us, actually, and you know we're invested in one of these sleep apnea drugs. It's not a weight loss drug. It actually goes to the core of trying to treat sleep apnea, which is called ApneMed. We're going to partner with pharma in this space. We've seen the substitute of the sort of tiny, sort of whatever it is, 0.5% of patient flow into these implanted devices. and there's a company out there doing, I think, lots of very expensive advertising, but it's driving lots of patients into the funnel. It's demand gen for us because, you know, they market it as a button to treat sleep apnea, but it's actually an implanted medical device the size of a pacemaker that goes into the chest. When the patient finds that out, they say, well, what are the alternatives? Oh, there's a non-invasive alternative like CPAP or APAP or Biolab, and the patient goes online with that. I think some of the pharmaceutical advertising in this space will drive us to the 80% of undiagnosed patients in the space to say, hey, look, I'll take the pill first and maybe then I need sleep apnea therapy or vice versa. But we think there's a lot of opportunity to partner here with pharma. We're already partnering with our propeller division with some of the COPD and asthma drug delivery. I look forward to, not just with apnea med, but these other obesity drugs to understand how they drive patients into the funnel and how we work with them to treat those patients.
spk04: Thank you. We've reached the end of our question and answer session. I'd like to turn the floor back over to Mick for any further closing comments.
spk06: Well, thanks, Kevin, and thank you again to all of our stakeholders for joining us on the call. I'd once again like to take the opportunity to thank the 10,000 ResMedians. Many of you are also shareholders, so thank you for what you do and for investing in our company as well. Thank you for your dedication, hard work, helping people sleep better, breathe better, and live better lives. In 140 countries, you delivered these numbers that we just reported. Thank you for all that you do. I'll hand the call back to Amy, and then we'll close out.
spk10: Great. Thank you, Mick. Thanks, Kevin, and thanks, everyone. We appreciate your interest and your time. If you do have any questions, additional questions, please don't hesitate to reach out directly. This does conclude our third quarter 2023 conference call. Kevin, you can now close us out.
spk04: Thank you. That does conclude today's teleconference and webcast. You may disconnect your lines at this time and have a wonderful day. We thank you for your participation today.
Disclaimer